Answers are grounded in this paper and cite their sources.
Asparaginase drugs are integrated to multicomponent chemotherapy protocols for acute lymphoblastic leukemia (ALL) in children and adults. Despite the use of different treatment protocols for ALL therapy, drugs are the same there and the differences include the doses and the frequency of administration of cytostatics. Native L-asparaginase obtained from Escherichia coli was the first asparaginase drug for the treatment of ALL. With accumulated knowledge about undesirable and side effects another asparaginase drugs with less expressed side effects were created: pegylated form (PEG-asparaginase), asparaginase derived from Erwinia chrysanthemi (erwinase) and pegylated form of erwinase (crisantaspase). This review is devoted to modern ideas about the mechanisms of action of various asparaginase drugs, pharmacological properties and adverse effects. There is a particular attention to the development of new forms of asparaginase, which will help minimize side effects and increase the effectiveness of the drug. Of no less importance is drug monitoring of asparaginase in the blood to detect side effect at the time and to understand the effectiveness of the therapy. The introduction of drug monitoring will help to individualize and improve the effectiveness of ALL treatment.
No takes yet. Share an insight, caveat, or question.
Korkina et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: